Letters (Westmoreland)

Letter to the editor: Oppenheimer, cancer parallels

Tribune-Review
By Tribune-Review
2 Min Read Aug. 25, 2023 | 2 years Ago
Go Ad-Free today

From the movie “Oppenheimer” and some independent research, I learned that it took three years for the Manhattan Project to develop the atomic bomb. This is less time than the Pennsylvania Department of Health and the University of Pittsburgh took for their longterm studies on a group of rare childhood cancers in Washington County. I believe there are a few more parallels between these two studies or developments.

“Oppenheimer” neglected to mention Canonsburg’s role and sacrifices in the processing of uranium and the development of the atomic bomb, but, back in the 1920s, Marie Curie did a few studies in Canonsburg that led to the processing and storing of significant amounts of uranium in Canonsburg, from 1911 till today. Also, the Curie and Canonsburg contributions on studies of radiation were very important and instrumental in the development of the atomic bomb, plus many future scientific discoveries with radium. Curie died of radiation-induced leukemia.

At the end of the movie and life of Oppenheimer, he and Albert Einstein seemingly regretted their roles in developing the atomic bomb and the results that led to an unknown number of deaths.

Do we think the commission and the results of the Pennsylvania study on cancer clusters in Canonsburg will reveal and/or regret an unknown number of deaths, like the Manhattan Project? Do we think?

Dennis Smiddle

Canonsburg

The writer is a Pennsylvania representative for Citizens for Radioactive Radon Reduction.

Share

Tags:

About the Writers

Push Notifications

Get news alerts first, right in your browser.

Enable Notifications

Content you may have missed

Enjoy TribLIVE, Uninterrupted.

Support our journalism and get an ad-free experience on all your devices.

  • TribLIVE AdFree Monthly

    • Unlimited ad-free articles
    • Pay just $4.99 for your first month
  • TribLIVE AdFree Annually BEST VALUE

    • Unlimited ad-free articles
    • Billed annually, $49.99 for the first year
    • Save 50% on your first year
Get Ad-Free Access Now View other subscription options